CRNX
Crinetics Pharmaceuticals Inc
NASDAQ: CRNX · HEALTHCARE · BIOTECHNOLOGY
$38.78
+0.88% today
Updated 2026-04-30
Market cap
$3.99B
P/E ratio
—
P/S ratio
519.04x
EPS (TTM)
$-4.95
Dividend yield
—
52W range
$26 – $58
Volume
1.1M
Crinetics Pharmaceuticals Inc (CRNX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-5.47M | $-9.48M | $-19.46M | $-46.38M | $-62.03M | $-88.59M | $-115.20M | $-166.31M | $-225.97M | $-377.92M |
| Capital expenditures | $190000.00 | $304000.00 | $1.06M | $492000.00 | $186000.00 | $436000.00 | $1.66M | $4.69M | $3.84M | $5.76M |
| Depreciation | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $270000.00 | $271000.00 | $2.32M | $6.29M | $10.43M | $17.35M | $28.27M | $40.94M | $69.39M | $91.02M |
| Free cash flow | $-5.66M | $-9.78M | $-20.52M | $-46.87M | $-62.21M | $-89.02M | $-116.86M | $-171.00M | $-229.81M | $-383.68M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $31.28M | $-4.65M | $52.76M | — | — | — | — | — |